Natera
308 articles about Natera
-
Natera Announces Real-World Data Collaboration with Merck
11/14/2023
Natera, Inc. today announced that it has entered into an agreement with Merck, under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research.
-
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
11/8/2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG).
-
Natera Reports Third Quarter 2023 Financial Results
11/8/2023
Natera, Inc., a global leader in cell-free DNA testing, reported financial results for the third quarter ended September 30, 2023.
-
Natera to Participate in November Investor Conferences
11/7/2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November.
-
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
11/2/2023
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight ™ in Chronic Kidney Disease.
-
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
10/22/2023
Natera, Inc. announced updated data from the GALAXY arm of the CIRCULATE-Japan trial further showcasing the ability of the Signatera™ molecular residual disease test to help identify patients with resectable colorectal cancer who are at an increased risk of recurrence and predict who are most likely to benefit from adjuvant chemotherapy.
-
Natera to Report its Third Quarter 2023 Results on November 8
10/20/2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2023, after the market close on Nov. 8, 2023.
-
Foundation Medicine and Natera Announce Broad Clinical Launch and Medicare Coverage of FoundationOne®Tracker
10/10/2023
FoundationOne ® Tracker is now available to all physicians in the United States seeking personalized monitoring of their patients’ response to treatment.
-
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
10/4/2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Frontiers in Oncology demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to detect progression early, with high sensitivity and specificity, and risk stratify patients with unresectable stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiotherapy.
-
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
10/3/2023
Natera, Inc., a global leader in cell-free DNA testing, announced that the United States Supreme Court denied CareDx, Inc.’s petition for certiorari concerning a patent infringement lawsuit brought by CareDx against Natera.
-
Natera Submits First PMA Module to the FDA for Signatera™
10/2/2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the submission of the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, as a companion diagnostic (CDx) assay for patients with muscle-invasive bladder cancer (MIBC).
-
Natera Announces Senior Leadership Appointments - September 18, 2023
9/18/2023
Natera, Inc., a global leader in cell-free DNA testing, announced three appointments within its senior leadership team, effective immediately.
-
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
9/14/2023
Natera, Inc. (NASDAQ: NTRA) today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, to monitor response to neoadjuvant therapy in breast cancer patients across all subtypes.
-
Natera Announces Pricing of $250 Million Follow-On Offering
9/7/2023
Natera, Inc., a global leader in cell-free DNA testing, announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share.
-
Natera Launches Proposed Follow-On Offering - September 06, 2023
9/6/2023
Natera, Inc., a global leader in cell-free DNA testing, announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock.
-
Natera to Participate in Upcoming September 2023 Investor Conferences
9/1/2023
Natera, Inc., a global leader in cell-free DNA testing, announced that members of its management team will present at the following investor conferences: The Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11 at 4:55 p.m. ET in New York, NY The Baird 2023 Global Healthcare Conference on Tuesday, Sept.
-
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
8/16/2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX).
-
Natera Reports Second Quarter 2023 Financial Results
8/3/2023
Natera, Inc., a global leader in cell-free DNA testing, reported financial results for the second quarter ended June 30, 2023.
-
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
8/2/2023
Natera, Inc. announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA.
-
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
7/28/2023
Natera, Inc. today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297).